title: Selenoprotein P in plasma in relation to cancer morbidity in middle-aged Swedish men.
abstract: The premorbid level of selenoprotein P in plasma from subjects with cancer at different sites was compared with that from control subjects in a nested case-control study. A health screening of 12,500 middle-aged men was performed during 1974-1982 in Malmö, Sweden, and from the 400 cancer cases that were identified during follow-up until the end of 1988, 302 plasma samples were available for analysis of selenoprotein P. Two living controls per case of the same screening day and age were chosen. Selenoprotein P levels in subgroups of major cancer sites were lower in cases than in controls for the respiratory tract (1.20 and 1.30 arbitrary units, respectively; p < 0.05) cancer group. The odds ratio for overall cancer risk in the lowest quintile of selenoprotein P level compared with that in the highest was 5.2 [p (for trend) = 0.01]. In subgroups of major cancer sites, the odds ratios for cancer risk in the lowest tertile compared with the highest were 6.0 [p (for trend) = 0.004] in the respiratory tract and 3.4 [p (for trend) = 0.002] in the digestive tract. In cases + controls, selenoprotein P was lower in smokers than in nonsmokers (p < 0.05). Selenoprotein P was significantly correlated to plasma albumin, fasting blood glucose, and body mass index and inversely correlated to plasma alpha 1-antitrypsin and gamma-glutamyl transferase. The results suggest that a low plasma selenoprotein P level is associated with higher future risk of respiratory and digestive tract cancer in middle-aged men.
authors.affiliation: Division of Biomedical Nutrition, Lund University, Sweden.
authors.forename: M E
authors.initials: ME
authors.lastname: Persson-Moschos
authors.forename: L
authors.initials: L
authors.lastname: Stavenow
authors.forename: B
authors.initials: B
authors.lastname: Akesson
authors.forename: F
authors.initials: F
authors.lastname: Lindgärde
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D016022:Case-Control Studies; D015331:Cohort Studies; D004067:Digestive System Neoplasms / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D009369:Neoplasms / Q000097:blood* / Q000453:epidemiology*; D016017:Odds Ratio; D011506:Proteins / Q000032:analysis*; D012142:Respiratory Tract Neoplasms / Q000097:blood; D012307:Risk Factors; D051149:Selenoprotein P; D051140:Selenoproteins; D012709:Serum Albumin / Q000032:analysis; D012907:Smoking / Q000097:blood; D013548:Sweden; D014571:Urologic Neoplasms / Q000097:blood; D000515:alpha 1-Antitrypsin / Q000032:analysis; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D001786:Blood Glucose; D011506:Proteins; D051149:Selenoprotein P; D051140:Selenoproteins; D012709:Serum Albumin; D000515:alpha 1-Antitrypsin; D005723:gamma-Glutamyltransferase